John H. Patel; David Günther; Xing Li; Fang Liu; Yi Zhang; Paritosh B. Pannala; Jeffrey A. Lubezky
Abstract
Renal cancer is one of the most lethal human cancers and continues to be a major unsolved health problem. Conventional treatment approaches such as surgery, radiation, Immunotherapy, chemotherapy, or a combination thereof have had little impact on the course of this aggressive cancer and early cancer detection remains a major challenge in renal cancer but holds promise of resulting in a more favorable disease outcome. Circulating microRNAs (c-miRNAs) provide a new dimension as clinical biomarkers for disease diagnosis. In the current study we present a validated miRNA signature to predict biomarker panel for early diagnosis of renal cancer. The miRNA expression signature was profiled using custom miRNA microarray chips covering 8442human miRNAs derived from the miRBase database, version 16, released in 2010. These findings indicated that isolation and characterization of c-miRNAs may be a useful biomarker for prognosis, disease recurrence and early detection using cellular and molecular biology techniques from the circulation of renal cancer patients.
Keywords: Renal cell cancer; miRNA; Immunotherapy; Early diagnosis; Molecular biology
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. [Full Article (HTML)]
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29. [PubMed]
3. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011;91:827-887. [PubMed]
4. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56(11):1733-1741. [Abstract/FREE Full Text]
5. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010;101(10): 2087-2092. [PubMed]
6. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4:199-227. [PubMed]
7. National Cancer Institute: PDQ Renal Cell Cancer Treatment. Bethesda, Md: National Cancer Institute. Date last modified: Feb. 21, 2014. Available at: http://cancer.gov/cancertopics/. Accessed: March 23, 2014.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney cancer. Version 2.2014. Available at: http: //www.nccn.org. Accessed: March 23, 2014.
9. Pili R, Kauffman E, Rodriguez R. Cancer of the kidney. In: Niederhuber JE, Armitage JO, Doroshow JH, et al., eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2013:chap 82.
10. Hu J, Mao Y, White K. Renal cell carcinoma and occupational exposure to chemicals in Canada. Occup Med (Lond) 2002; 52(3):157-64. [Medline]
11. Cho E, Curhan G, Hankinson SE, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med 2011;171(16):1487-93. [Medline]
12. Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P, et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008;101(8): 949-58. [Medline]
13. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2):115-24. [Medline]
14. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol 2010;3:109-113. [PubMed]
15. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011;39:D152-D157. [PubMed]
16. Sharov AA, Dudekula DB, Ko MS. A web-based tool for principal component and significance analysis of microarray data. Bioinformatic 2005; 21: 2548-2549. [PubMed]
17. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-11. [Medline]
18. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013; 49(6):1287-96. [Medline]
19. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-81. [Medline]
20. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27(20): 3312-8. [Medline]
21. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-622. [PubMed]
22. Christense ME, Carolan BS, Smith GT. Notch signaling in pathogenesis of diseases. American Journal of BioMedicine 2013;1:19-22. [Abstract/Full-Text]
23. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116(5):1272-80. [Medline]
24. Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol 2008; 26(14): 2285-91. [Medline]
25. Saad Z, Arif M, Yassen N, Jasim H, Jelawe M, Brown J. Novel expression of microRNAs in serum samples of Iraqi breast cancer women. American Journal of BioMedicine 2014; 2(5):567–574. [Abstract/Full-Text]
26. Mukund A, Gamanagatti S. Ethanol ablation of renal cell carcinoma for palliation of symptoms in advanced disease. J Palliat Med 2010;13(2):117-20. [Medline]
27. Purdue MP, Moore LE, Merino MJ, Boffetta P, Colt JS, Schwartz KL, et al. An investigation of risk factors for renal cell carcinoma by histologic subtype in two case-control studies. Int J Cancer 2013;132(11):2640-7. [Medline]
28. Mukund A, Gamanagatti S. Ethanol ablation of renal cell carcinoma for palliation of symptoms in advanced disease. J Palliat Med 2010;13(2):117-20. [Medline]
29. Polioudakis D, Bhinge AA, Killion PJ, Lee BK, Abell NS, Iyer VR. A Myc-microRNA network promotes exit from quiescence by suppressing the interferon response and cell-cycle arrest genes. Nucleic Acids Res 2013;41:2239-2254. [PubMed]
30. Grasedieck S, Sorrentino A, Langer C, et al. Circulating microRNAs in hematological diseases: principles, challenges, and perspectives. Blood 2013;121(25): 4977-4984.
31. Ling B, Wang GX, Long G, Qiu JH, Hu ZL. Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol 2012;138:1355-1361. [PubMed]
32. Ting Y, Medina DJ, Strair RK, Schaar DG. Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression. Biochem Biophys Res Commun 2010; 394: 606-611. [PubMed]
33. Patel JB, Appaiah HN, Burnett RM, Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S, Steeg P. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene 2011; 30:1290-1301. [PubMed]
